| Value | ₹139.5 Cr |
|---|---|
| Execution period | Expected completion by July 17, 2026 |
BSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,871.80
- Market cap
- ₹35,510 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 35.1×Sector 45.9×
- Promoter holding
- 77.82%-0.01% QoQ
- FII holding
- 4.94%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Other Announcement
Emcure Pharmaceuticals submitted its quarterly shareholding pattern for the period ended September 30, 2026. This filing is a routine regulatory compliance disclosure under SEBI.
Emcure Pharmaceuticals Board Meeting Date
Emcure Pharmaceuticals will hold a board meeting on November 03, 2026, to consider and approve the company's standalone and consolidated financial results for the quarter.
Emcure Pharmaceuticals Acquisition
Emcure Pharmaceuticals approved the merger of its wholly-owned subsidiaries, Zuventus Healthcare and Emcutix Biopharmaceuticals, into itself. The internal restructuring involves no cash consideration or share issuance.
Emcure Pharmaceuticals Legal & Regulatory
Emcure Pharmaceuticals received Income-tax Department orders imposing aggregate penalties of Rs. 57.74 Crore for assessment years 2015-16 to 2021-22. The company is evaluating legal remedies.
- Value
- ₹57.74 Cr
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Other merger & restructuring announcements
All →Symphony Merger & Restructuring Worth ₹27 Cr
Symphony will sell its Bodakdev vacant land for ₹27 Crore, versus ₹5.68 Crore book value. Sale deed is expected November 6, 2026; operations are unaffected.
- Value
- ₹27.00 Cr
Juniper Green Energy Merger & Restructuring Worth ₹0.15 Cr
Juniper Green Energy incorporated wholly owned subsidiary Juniper Green Beta Fifteen Private Limited on October 30, 2026. The company subscribed to 1,50,000 shares for Rs.0.15 Crore.
- Value
- ₹0.15 Cr
Oricon Enterprises Merger & Restructuring Worth ₹145 Cr
Oricon Enterprises sold its leasehold land and building to Anand Rathi Towers for Rs.145 Crore. The sale is completed and the buyer is unrelated to promoters.
- Value
- ₹145.0 Cr
Clean Max Enviro Energy Solutions Merger & Restructuring Worth ₹0 Cr
Sale of 26% stake in subsidiary Clean Max Alps to Bayer Vapi for ₹0.0026 Crore. The subsidiary contributed no revenue or net worth last financial year.
- Value
- ₹0.00 Cr
Vimta Labs Merger & Restructuring Worth ₹0.08 Cr
Vimta Labs incorporated wholly owned US subsidiary Vimta Labs LLC, investing about INR 0.08 Crore (USD 8,500). The contract research unit supports the parent's testing business.
- Value
- ₹0.08 Cr
Weagro Merger & Restructuring Worth ₹0.01 Cr
Weagro will incorporate a wholly-owned Singapore subsidiary, Weagro Pte Ltd, with initial investment up to SGD 100,000. The move expands its agro business into Singapore.
- Value
- ₹0.01 Cr
- Execution
- Within two months from the date of the Board decision, subject to statutory approvals.